GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » EV-to-FCF

Taiko Pharmaceutical Co (TSE:4574) EV-to-FCF : (As of Apr. 01, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Taiko Pharmaceutical Co's Enterprise Value is 円11,554 Mil. Taiko Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was 円0 Mil. Therefore, Taiko Pharmaceutical Co's EV-to-FCF for today is .

The historical rank and industry rank for Taiko Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

TSE:4574' s EV-to-FCF Range Over the Past 10 Years
Min: -5.78   Med: 0   Max: 0
Current: -5.78

TSE:4574's EV-to-FCF is ranked worse than
100% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.5 vs TSE:4574: -5.78

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-01), Taiko Pharmaceutical Co's stock price is 円281.00. Taiko Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was 円-49.903. Therefore, Taiko Pharmaceutical Co's PE Ratio (TTM) for today is At Loss.


Taiko Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Taiko Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co EV-to-FCF Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.19 15.92 17.41 -10.82 -8.41

Taiko Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Taiko Pharmaceutical Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiko Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's EV-to-FCF falls into.


;
;

Taiko Pharmaceutical Co EV-to-FCF Calculation

Taiko Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11554.433/0
=

Taiko Pharmaceutical Co's current Enterprise Value is 円11,554 Mil.
Taiko Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taiko Pharmaceutical Co  (TSE:4574) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Taiko Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=281.00/-49.903
=At Loss

Taiko Pharmaceutical Co's share price for today is 円281.00.
Taiko Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-49.903.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Taiko Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiko Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co Headlines

No Headlines